This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies
Biomarker Research Open Access 29 March 2023
-
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
Journal of Hematology & Oncology Open Access 22 October 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Palumbo A, Rajkumar SV . Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449–456.
Spaapen RM, Groen RW, van den Oudenalder K, Guichelaar T, van Elk M, Aarts-Riemens T et al. Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen. Clin Cancer Res 2010; 16: 5481–5488.
Pratt G, Goodyear O, Moss P . Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563–579.
Frassanito MA, Cusmai A, Dammacco F . Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001; 125: 190–197.
Gabrilovich DI, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162–174.
Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233–4244.
Greten TF, Manns MP, Korangy F . Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11: 802–807.
Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K . The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000; 1: 351–356.
Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72: 540–547.
Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182: 5693–5701.
Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170: 270–278.
Rodriguez PC, Hernandez CP, Morrow K, Sierra R, Zabaleta J, Wyczechowska DD et al. L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol 2010; 185: 5198–5204.
Kusmartsev S, Gabrilovich DI . Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003; 74: 186–196.
Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409–421.
Yang L, Edwards CM, Mundy GR . Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res 2010; 25: 1701–1706.
Acknowledgements
We would like to thank Angelo Willems and Carine Seynaeve for their expert technical assistance. The work was financially supported by the International Myeloma Foundation, Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO-Vl), Stichting tegen Kanker, King Baudouin Foundation, Multiple Myeloma Research Foundation, the European Stem cell network (EUFP6 MSCNET) and the Onderzoeksraad Vrije Universiteit Brussel (GOA48, OZR-VUB). E Van Valckenborgh, E Menu and E De Bruyne are postdoctoral fellows, and E Schouppe and K Movahedi are predoctoral fellows of FWO-Vl. JA Van Ginderachter is supported by Stichting tegen Kanker. OT-1 mice were a kind gift of Dr Muriel Moser (ULB, Brussels, Belgium). Non-labeled anti-CCR2 (MC-21) was a gift of Dr Matthias Mack (University of Regensburg, Germany).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Van Valckenborgh, E., Schouppe, E., Movahedi, K. et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia 26, 2424–2428 (2012). https://doi.org/10.1038/leu.2012.113
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.113
This article is cited by
-
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies
Biomarker Research (2023)
-
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
Journal of Hematology & Oncology (2019)
-
Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment
Journal of Cancer Research and Clinical Oncology (2019)
-
Bone marrow myeloid cells in regulation of multiple myeloma progression
Cancer Immunology, Immunotherapy (2017)
-
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Cellular and Molecular Life Sciences (2016)